Off-target toxicity and poor localization limit therapeutic efficacy. Enhancing specificity prevents systemic damage and increases drug concentration at the tumor site.

Tumors frequently develop mechanisms to bypass standard immunotherapy, leading to treatment failure. Overcoming this resistance restores the efficacy of the immune system in targeting malignant cells.

Limited systemic tolerability and inadequate tumor-specific toxicity of existing Nectin-4 treatments. Improving the ratio of efficacy to toxicity enables higher dosing and better patient outcomes.